The North America Transcatheter Aortic Valve Replacement Market would witness market growth of 6.3% CAGR during the forecast period (2022-2028).
The TAVR devices have higher safety-related benefits, according to several recently published studies. These studies also conclude a decreased incidence of paravalvular regurgitation, valve embolization, and other bleeding events when transcatheter heart valve devices are used. In addition, technology development is quite popular in the rapidly evolving transcatheter aortic valve replacement market.
This factor will encourage the growth of the transcatheter heart valve replacement market. Cardiovascular specialists at the forefront of healthcare who use ground-breaking research, cutting-edge technology, and transcatheter aortic valve replacement (TAVR) to treat some of the most complicated heart problems are in charge of numerous extensive initiatives. TAVR is a novel, quickly evolving therapy that provides patients with the best TAVR technology.
According to the CDC's data, heart disease remains the leading cause of mortality in the United States for men, women, and members of the majority of racial and ethnic groups. In the US, cardiovascular disease claims one life every 34 seconds. 1 in 5 deaths in the United States in 2020 was caused by heart disease, which claimed about 697,000 lives. Throughout 2017 and 2018, the cost of heart disease in the US was roughly $229 billion. Valvular heart disease affects 2.5% of Americans, but older persons are more likely to develop it. Valvular heart disease affects roughly 13% of those born before 1943.
The US market dominated the North America Transcatheter Aortic Valve Replacement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,129.3 million by 2028. The Canada market is poised to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Material, the market is segmented into Nitinol, Stainless Steel, Cobalt-Chromium and Others. Based on Implantation Procedure, the market is segmented into Transfemoral, Transapical and Transaortic. Based on Mechanism, the market is segmented into Balloon-expanding Valve and Self-expanding Valve. Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Transcatheter Aortic Valve Replacement Market is Predict to reach $8 Billion by 2028, at a CAGR of 7.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
By Material
By Implantation Procedure
By Mechanism
By End-use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
